DOCSLIB.ORG

LIST of REGISTRED OTC DRUGS in ARMENIA (Up to 31.03.2017)

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
LIST of REGISTRED OTC DRUGS in ARMENIA (Up to 31.03.2017) LIST OF REGISTRED OTC DRUGS IN ARMENIA (Up to 31.03.2017) International nonproprietary Registration Term of Legal status for N Trade name name (generic) or Drug form Dose and packaging Manufacturer Country ATC1 code License holder number registration supply active ingredients name Help S.A ,10 ambroxol Help S.A. Pedini, Valaoritou str., GR 6mg/ml, 09.03.2016 1 Abrobion (ambroxol syrup Ioanninon, Ioannina, Greece R05CB06 15404 OTC 144 52, 125ml glass bottle 09.03.2021 hydrochloride) 45500 Metamorphosis, Attika, Greece Salutas Pharma GmbH, Otto-von- Guericke-Alle-1, 100mg/5ml, 39179 Barleben-batch Sandoz 30g powder in 75ml glass powder for oral releaser, Allphamed Pharmaceuticals d.d., bottle and measuring 20.10.2015 2 ACC acetylcysteine solution with orange Pharbil Arzneimittel Germany R05CB01 14947 OTC Verovskova Str. 57, spoon 5ml, 60g powder in 20.10.2020 flavour GmbH Hildebrandstr. 1000 Ljubljana, 150ml glass bottle and 12, 37081 Gottingen, Slovenia measuring spoon 5ml Germany-bulk manufacturer, packager Salutas Pharma GmbH, Otto-von- Guericke-Alle-1, 39179 Barleben - Sandoz batch releaser Pharmaceuticals d.d., 100mg, 21.11.2014 3 ACC 100 acetylcysteine tablets effervescent (Hermes Pharma Germany R05CB01 13967 OTC Verovskova Str. 57, in plastic container (20) 21.11.2019 G.m.b.H., Allgau 36, 1526 Ljubljana, A-9400 Wolsberg, Slovenia Germany - bulk manufacturer, packager) 1 Salutas Pharma GmbH, Otto-von- Guericke-Alle-1, Sandoz 39179 Barleben-batch Pharmaceuticals d.d., powder for oral 100mg, releaser, Lindopharm 14.04.2015 4 ACC 100 acetylcysteine Germany R05CB01 14430 OTC Verovskova Str. 57, solution 3g sachets (20) GmbH, Neustrasse 82, 14.04.2020 1000 Ljubljana, D-40721 Hilden, Slovenia Germany- bulk manufacturer, packager Salutas Pharma GmbH, Otto-von- Guericke-Alle-1, 39179 Barleben - Sandoz batch releaser Pharmaceuticals d.d., 200mg, 21.11.2014 5 ACC 200 acetylcysteine tablets effervescent (Hermes Pharma Germany R05CB01 13968 OTC Verovskova Str. 57, in plastic container (20) 21.11.2019 G.m.b.H., Allgau 36, 1526 Ljubljana, A-9400 Wolsberg, Slovenia Germany - bulk manufacturer, packager) Salutas Pharma GmbH, Otto-von- Guericke-Alle-1, Sandoz 39179 Barleben-batch Pharmaceuticals d.d., powder for oral 200mg, releaser, Lindopharm 14.04.2015 6 ACC 200 acetylcysteine Germany R05CB01 14431 OTC Verovskova Str. 57, solution 3g sachets (20) GmbH, Neustrasse 82, 14.04.2020 1000 Ljubljana, D-40721 Hilden, Slovenia Germany- bulk manufacturer, packager Salutas Pharma GmbH, Otto-von- Guericke-Alle-1, Sandoz 39179 Barleben-batch Pharmaceuticals d.d., powder for oral 200mg, releaser, Lindopharm 25.03.2015 7 ACC Hot Drink acetylcysteine Germany R05CB01 14367 OTC Verovskova Str. 57, solution 3g sachets (20) GmbH, Neustrasse 82, 25.03.2020 1000 Ljubljana, D-40721 Hilden, Slovenia Germany- bulk manufacturer, packager 2 Salutas Pharma GmbH, Otto-von- Guericke-Alle-1, Sandoz 39179 Barleben-batch Pharmaceuticals d.d., 600mg, releaser, Hermes 25.03.2015 8 ACC Long acetylcysteine tablets effervescent Germany R05CB01 14362 OTC Verovskova Str. 57, in plastic container (10) Arzneimittel GmbH, 25.03.2020 1000 Ljubljana, Hans-Urmiler Ring Slovenia 52, Wolfratshausen, Germany-packager, bulk manufacturer Borisov Medical Borisov Medical Preparations Plant Preparations Plant OJSC, 64/27, 500mg, 25.10.2012 9 Acetylsalicylic acid acetylsalicylic acid tablets OJSC, 64/27, Belarus N02BA01 11846 OTC Chapayev str., in blister (10) 25.10.2017 Chapayev str., Borisov Borisov 222120, 222120, Minsk oblast Minsk oblast, BELARUS Technolog PJSC, Technolog PJSC, Manuylskogo str. 8, 500mg, Manuylskogo str. 8, 09.04.2013 10 Acetylsalicylic acid acetylsalicylic acid tablets Ukraine N02BA01 12334 OTC 20300 Uman, in blister (10) 20300 Uman, 09.04.2018 Cherkassy region, Cherkassy region UKRAINE Pharmstandard- Pharmstandard- 500mg, Leksredstva OJSC, Leksredstva OJSC, 14.08.2013 11 Acetylsalicylic acid acetylsalicylic acid tablets in blister 305022, Kursk, Russia N02BA01 12782 OTC 305022, Kursk, 14.08.2018 (10, 20/2x10/) Agregatnaya 2nd str., Agregatnaya 2nd str., 1a/18 1a/18, Russia Irbitskiy Irbitskiy himfarmzavod JSC, himfarmzavod JSC, 500mg, 09.12.2013 12 Acetylsalicylic acid acetylsalicylic acid tablets 643 RU, Irbit, St. Russia N02BA01 13087 OTC 643 RU, Irbit, St. in blister (10) 09.12.2018 Sverdlovsk, K. Marksa Sverdlovsk, Kirova str., 124 str., 172, Russia Arpimed LLC, Arpimed LLC, Kotayk Kotayk Marz, 500mg, Marz, Abovyan, 2nd Republic of 21.11.2014 13 Acetylsalicylic acid acetylsalicylic acid tablets N02BA01 13969 OTC Abovyan, 2nd Micro- in blister (10/1x10/) Micro-District, 19 Armenia 21.11.2019 District, 19 Building, Building Republic of Armenia Salutas Pharma Hexal AG, 50mg/g, GmbH, Lange 08.06.2015 Industriestrasse 25, D- 14 Acic aciclovir cream Germany D06BB03 14589 OTC 2g aluminium tube Goehren 3, 39171 08.06.2020 83607 Holzkirchen, Osterweddingen Germany 3 Farmaprim SRL, Farmaprim SRL, Crinilor str., 5, 50mg/g, Crinilor str., 5, 06.05.2014 15 Aciclovir aciclovir cream Moldova D06BB03 13462 OTC Porumbeni, Criuleni 2g, 10g aluminium tube Porumbeni, Criuleni 06.05.2019 dis., MD-4829, dis., MD-4829 Moldova Belmedpreparaty Belmedpreparaty ointment for 50mg/g, 25.11.2013 RUE, 220007, Minsk, 16 Aciclovir ointment aciclovir RUE, 220007, Minsk, Belarus D06BB03 13018 OTC external use 5g aluminium tube 25.11.2018 Fabritsius St., 30, Fabritsius St., 30 Belarus Akrikhin Akrikhin Pharmaceuticals Co., Pharmaceuticals Co., 142450, Moscow 142450, Moscow 50mg/g, 08.04.2015 17 Aciclovir-Akri aciclovir ointment region, Noginsk Russia D06BB03 14416 OTC region, Noginsk 5g aluminium tube 08.04.2020 district, Staraya district, Staraya Kupavna, Kirova Kupavna, Kirova street 29 street 29, Russia Lekko Lekko Pharmaceutical lactobacillus Pharmaceutical Company CJSC, acidophilus, not less than 107+0,4mg, 31.07.2012 Company CJSC, 18 Acipol capsules 601125, Vladimir Russia A07FA51 11633 OTC polysaccharide of in plastic container (30) 31.07.2017 601125, Vladimir region, village kefir fungus region, village Volginsky Volginsky, RUSSIA Arpimed LLC, Arpimed LLC, Kotayk Kotayk Marz, 20mg/ml, Marz, Abovyan, 2nd Republic of 18.09.2014 19 Acne Wash salicylic acid soap liquid D02AF 13863 OTC Abovyan, 2nd Micro- 100ml plastic container Micro-District, 19 Armenia 18.09.2019 District, 19 Building, Building Republic of Armenia Irbitskiy Irbitskiy himfarmzavod JSC, himfarmzavod JSC, 250mg, 02.12.2015 20 Activated charcoal activated charcoal tablets 643 RU, Irbit, St. Russia A07BA01 15009 OTC 643 RU, Irbit, St. in strip (10) 02.12.2020 Sverdlovsk, K. Marksa Sverdlovsk, Kirova str., 124 str., 172, Russia Tatchempharmprepar Tatchempharmprepar aty JSC, 420091 50mg/g, aty JSC, 420091 05.09.2014 21 Acyclovir aciclovir ointment Russia D06BB03 13809 OTC Kazan, str. 10g aluminium tube Kazan, str. 05.09.2019 Belomorskaya 260, Belomorskaya 260 Russia 4 Schering-Plough Labo Bayer Consumer Care 0,5mg/ml, N.V., Industriepark 07.10.2016 AG, Peter Merian- 22 Aerius desloratadine syrup 60ml, 120ml and Belgium R06AX27 13975/1 OTC 30 B-2220, Heist-op- 26.11.2019 Strasse 84, 4052 Basel, measuring spoon den-Berg Switzerland Schering-Plough Labo Bayer Consumer Care 5mg, N.V., Industriepark 09.09.2016 AG, Peter Merian- 23 Aerius desloratadine tablets film-coated Belgium R06AX27 14507/1 OTC blister (10/1x10/) 30 B-2220, Heist-op- 15.05.2020 Strasse 84, 4052 Basel, den-Berg Switzerland Pharma Wernigerode Pharma Wernigerode dry extract of horse GmbH, GmbH, chestnut seeds, 47,25mg/g+5mg/g, 20ml 07.12.2012 Dornbergsweg 35D- 24 Aescusan solution oral Dornbergsweg 35D- Germany C05CX 12010 OTC thiamine bottle 07.12.2017 38855 Wernigerode 38855 Wernigerode hydrochloride Saxony-Anhalt, Saxony-Anhalt GERMANY Cesra Arzneimittel Cesra Arzneimittel GmbH & Co. KG, horse chestnut 30mg, GmbH & Co. KG, C05CX03; 30.12.2016 25 Aescuven tablets coated Germany 16355 OTC Braunmattstr. 20, seeds in bllster (40/2x20/) Braunmattstr. 20, herbal drug 30.12.2021 Baden-Baden, 76532, Baden-Baden, 76532 Germany Altayvitamini CJSC, Altayvitamini CJSC, vitamin A, vitamin 100000IU+100mg, blister 659325, The Altay 15.01.2016 659325, The Altay 26 Aevit-AV capsules Russia A11JA 13088/1 OTC E (10/1x10/, 30/3x10/) territory, Biysk, 69 09.12.2018 territory, Biysk, 69 Zavodskaya Str. Zavodskaya Str., Russia NPF Materia Medica antibodies to 3mg (not more than 10- NPF Materia Medica G04CX Holding Ltd., 9 bld., prostatospecific 15ng/g), Holding Ltd., 54, 21.01.2014 27 Afala tablets to be sucked Russia homeopathic 12512/1 OTC 3rd Samotyochny antigen affinity in blister (20/1x20/, Buguruslanskaya st., 01.06.2018 drug per., Moscow 127473, purified 40/2x20/, 100/5x20/) Chelyabinsk 454139 Russia gentiana D1, 1ml/100ml+ 10ml/100ml+ aconitum D6, 10ml/100ml+ Richard Bittner AG, R05X; Richard Bittner AG, bryonia D6, ferrum 10ml/100ml+ 20.07.2016 28 Aflubin drops oral Ossiacherstrasse 7, A- Austria homeopathic 15785 OTC Reisnerstrasse 55-57, phosphoricum D12, 10ml/100ml, 20.07.2021 9560 Feldkirchen drug A-1030 Wien, Austria acidum 20ml, 50ml glass bottle- sacrolacticum D12 dropper 5 gentiana D1, 3,6mg+37,2mg+ aconitum D6, Richard Bittner AG, R05X; Richard Bittner AG, 37,2mg+37,2mg+ 37,2mg, 20.07.2016 29 Aflubin bryonia D6, ferrum tablets sublingual Ossiacherstrasse 7, A- Austria homeopathic 15786 OTC Reisnerstrasse 55-57, in blister (12/1x12/, 20.07.2021 phosphoricum D12, 9560 Feldkirchen drug A-1030 Wien, Austria 24/2x12/, 48/4x12/) acidum sacrolacticum D12 Esco-Pharm LLC, Nor- sulfacetamide Esco-Pharm LLC, Nor- powder for external 500mg, Republic of 17.09.2013 Norq, Mikoyan
Load more

Recommended publications
  • Complementary and Alternative Treatments for Alopecia: a Comprehensive Review
    Review Article Skin Appendage Disord 2019;5:72–89 Received: April 22, 2018 DOI: 10.1159/000492035 Accepted: July 10, 2018 Published online: August 21, 2018 Complementary and Alternative Treatments for Alopecia: A Comprehensive Review Anna-Marie Hosking Margit Juhasz Natasha Atanaskova Mesinkovska Department of Dermatology, University of California, Irvine, Irvine, CA, USA Keywords Introduction Alopecia · Complementary and alternative medicine · Efficacy According to the National Center for Complementary and Integrative Health (NCCIH), a branch of the Nation- al Institutes of Health (NIH; Bethesda, MD, USA), more Abstract than 30% of adults and 12% of children utilize treatments The treatment of alopecia is limited by a lack of therapies developed “outside of mainstream Western, or conven- that induce and sustain disease remission. Given the nega- tional, medicine,” with a total USD 30.2 billion out-of- tive psychosocial impact of hair loss, patients that do not pocket dollars spent annually [1]. In the treatment of alo- see significant hair restoration with conventional therapies pecia, there is an unmet need for therapies providing sat- often turn to complementary and alternative medicine isfying, long-term results. Patients often turn to (CAM). Although there are a variety of CAM treatment op- complementary and alternative medicine (CAM) in an tions on the market for alopecia, only a few are backed by attempt to find safe, natural, and efficacious therapies to multiple randomized controlled trials. Further, these mo- restore hair. Although CAMs boast hair-growing poten- dalities are not regulated by the Food and Drug Administra- tial, patients may be disappointed with results as there is tion and there is a lack of standardization of bioactive in- a lack of standardization of bioactive ingredients and lim- gredients in over-the-counter vitamins, herbs, and supple- ited scientific evidence.
    [Show full text]
  • Airgid - Instructions for Use Im3 Airgid Is a Gelatin Collagen Sponge of Hemostatic Action to Which 5 % Colloidal Silver Is Added
    Airgid - Instructions for Use iM3 Airgid is a gelatin collagen sponge of hemostatic action to which 5 % colloidal silver is added. It facilitates optimum wound treatment when applied to a surgical cavity and can be cut to the required size to fit smaller wound cavities. The evenly porous foam structure absorbs its own weight in blood several times over, promotes thrombocyte aggregation due to the large surface and fills the wound cavity. The plug thus formed has a constant volume, fits snugly and stabilises blood coagulum. This prevents the formation of fissures and secondary cavities which, without iM3 Airgid, could form by contraction of the blood coagulum and trigger infection due to the invasion of contaminated saliva. Does not block the callus formation. iM3 Airgid remains in the wound and completely absorbed within 3-4 weeks. The addition of colloidal silver has an antimicrobial effect and does not develop any body resistance. Unlike other potential antimicrobial additives, colloidal silver cannot be washed away from the sponge so that its insolubility produces a long-lasting depot effect. Gamma-ray sterilisation process finalizes the manufacturing cycle of the product. Composition: One iM3 Airgid Small Animal (10 × 10 × 10 mm) contains: Hardened gelatine Ph. Eur. 13.85 mg. Colloid silver Ph. Eur. 0.73 mg. One iM3 Airgid Equine (20 × 20 × 20 mm) contains: Hardened gelatine Ph. Eur. 110.8 mg. Colloid silver Ph. Eur. 5.8 mg. Indications: • Socket extraction as part of one or two-stage implant placement. • The general treatment of alveoli and wound cavities, e.g. after cystostomies, apical amputations, maxillary sinus perforations, following surgical removal of tumours or retained teeth.
    [Show full text]
  • WO 2014/167554 A2 16 October 2014 (16.10.2014) P O P C T
    (12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT) (19) World Intellectual Property Organization International Bureau (10) International Publication Number (43) International Publication Date WO 2014/167554 A2 16 October 2014 (16.10.2014) P O P C T (51) International Patent Classification: (81) Designated States (unless otherwise indicated, for every A61K 47/10 (2006.01) kind of national protection available): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, (21) International Application Number: BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DK, DM, PCT/IB20 14/060675 DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, (22) International Filing Date: HN, HR, HU, ID, IL, IN, IR, IS, JP, KE, KG, KN, KP, KR, 12 April 2014 (12.04.2014) KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, (25) Filing Language: English OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, (26) Publication Language: English SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, (30) Priority Data: zw. 1103/DEL/2013 12 April 2013 (12.04.2013) IN (84) Designated States (unless otherwise indicated, for every (71) Applicant: VYOME BIOSCIENCES PVT. LTD. kind of regional protection available): ARIPO (BW, GH, [IN/IN]; 459 F.I.E, First Floor, Patparganj Industrial Area, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, SZ, TZ, New Delhi 110092 (IN).
    [Show full text]
  • List of Union Reference Dates A
    Active substance name (INN) EU DLP BfArM / BAH DLP yearly PSUR 6-month-PSUR yearly PSUR bis DLP (List of Union PSUR Submission Reference Dates and Frequency (List of Union Frequency of Reference Dates and submission of Periodic Frequency of submission of Safety Update Reports, Periodic Safety Update 30 Nov. 2012) Reports, 30 Nov.
    [Show full text]
  • Curriculum 2015/2016
    218 Curriculum 2015/2016 5th year / spring semester The deadline of submitting the thesis is March 10, 2016 Pharmacy students perform a 4-month clerkship (3 successive months in public pharmacies, 1 month can be accomplished in pharmacy, pharmaceutical factory, galenical laboratory, university department or hospital pharmacy). Fees: From the academic year 2005/2006 fifth year pharmacy students have to pay the whole tuition fee for the second semester of the fifth year. INTERIM PRACTICE Pharmacy students are required to complete a compulsory practice in a pharmacy which must be accredited by the country concerned. At the completion of the practice an evaluation form should be filled in, signed, stamped and sent directly from the pharmacy or submitted by the student in a sealed envelope. (The form can be downloaded from our website). A “Letter of Acceptance ” completed by the pharmacy has to be presented at the Foreign Students’ Secretariat until May, 2016 . 2nd year pharmacy students must perform a practice of 4 weeks in a pharmacy. 3rd year pharmacy students must perform a practice of 4 weeks in a pharmacy. 4th year pharmacy students must perform a practice of 2 months in a pharmacy (pharmacy, pharmaceutical factory, galenical laboratory, university department or hospital/clinical pharmacy). Note: The precondition of starting the 2-month compulsory practice is completing all the courses of the first four years and acquiring 16 credits of elective subjects. 5th year pharmacy students must perform a 4-month clerkship in the second semester of the academic year. (3 successive months in public pharmacies and 1 month in a hospital/clinical pharmacy.) Curriculum 2015/2016 219 SYLLABUSES FOR 1ST YEAR PHARMACY STUDENTS PHYSICS-BIOPHYSICS 1st semester LECTURE Flow of fluids.
    [Show full text]
  • )&F1y3x PHARMACEUTICAL APPENDIX to THE
    )&f1y3X PHARMACEUTICAL APPENDIX TO THE HARMONIZED TARIFF SCHEDULE )&f1y3X PHARMACEUTICAL APPENDIX TO THE TARIFF SCHEDULE 3 Table 1. This table enumerates products described by International Non-proprietary Names (INN) which shall be entered free of duty under general note 13 to the tariff schedule. The Chemical Abstracts Service (CAS) registry numbers also set forth in this table are included to assist in the identification of the products concerned. For purposes of the tariff schedule, any references to a product enumerated in this table includes such product by whatever name known. Product CAS No. Product CAS No. ABAMECTIN 65195-55-3 ACTODIGIN 36983-69-4 ABANOQUIL 90402-40-7 ADAFENOXATE 82168-26-1 ABCIXIMAB 143653-53-6 ADAMEXINE 54785-02-3 ABECARNIL 111841-85-1 ADAPALENE 106685-40-9 ABITESARTAN 137882-98-5 ADAPROLOL 101479-70-3 ABLUKAST 96566-25-5 ADATANSERIN 127266-56-2 ABUNIDAZOLE 91017-58-2 ADEFOVIR 106941-25-7 ACADESINE 2627-69-2 ADELMIDROL 1675-66-7 ACAMPROSATE 77337-76-9 ADEMETIONINE 17176-17-9 ACAPRAZINE 55485-20-6 ADENOSINE PHOSPHATE 61-19-8 ACARBOSE 56180-94-0 ADIBENDAN 100510-33-6 ACEBROCHOL 514-50-1 ADICILLIN 525-94-0 ACEBURIC ACID 26976-72-7 ADIMOLOL 78459-19-5 ACEBUTOLOL 37517-30-9 ADINAZOLAM 37115-32-5 ACECAINIDE 32795-44-1 ADIPHENINE 64-95-9 ACECARBROMAL 77-66-7 ADIPIODONE 606-17-7 ACECLIDINE 827-61-2 ADITEREN 56066-19-4 ACECLOFENAC 89796-99-6 ADITOPRIM 56066-63-8 ACEDAPSONE 77-46-3 ADOSOPINE 88124-26-9 ACEDIASULFONE SODIUM 127-60-6 ADOZELESIN 110314-48-2 ACEDOBEN 556-08-1 ADRAFINIL 63547-13-7 ACEFLURANOL 80595-73-9 ADRENALONE
    [Show full text]
  • Genetic Basis of Resistance to Quaternary Ammonium Compounds – the Qac Genes and Their Role: a Review
    Veterinarni Medicina, 57, 2012 (6): 275–281 Review Article Genetic basis of resistance to quaternary ammonium compounds – the qac genes and their role: a review Z. Jaglic, D. Cervinkova Veterinary Research Institute, Brno, Czech Republic ABSTRACT: Although the qac genes are named after one of their main substrates (i.e., quaternary ammonium compounds), these genes also code for resistance to a broad spectrum of other cationic compounds such as inter- calating dyes, diamidines and biguanides. The various Qac proteins are involved in relatively low specific efflux- based multidrug pumps and belong to a family of small multidrug resistance proteins. Even though the practical significance of qac-mediated resistance lies mainly in resistance to antiseptics, contradictory findings on this issue are still reported. Therefore, the aim of this review is to summarise the current knowledge on qac-mediated resistance with special emphasis on resistance to antiseptics and its relevance for practice. Keywords: antimicrobial; disinfectant; biocide; benzalkonium; chlorhexidine; cation; susceptibility Contents 3.2. Substrates of qac-mediated resistance 1. Introduction 3.3. Adaptive response to antiseptics 2. The qac genes and their distribution 4. The qac genes and resistance to antibiotics 3. Qac-mediated resistance 5. Conclusions 3.1. Mechanisms of qac-mediated resistance 6. References 1. Introduction first described genetic determinant of resistance to antiseptics was the qacA gene found on pSK1 Resistance to intercalating dyes (i.e. acriflavine and β-lactamase/heavy metal resistance plasmids and ethidium) was associated with particular ge- (Gillespie et al. 1986; Lyon and Skurray 1987). A netic elements, namely staphylococcal β-lactamase range of other qac genes linked with particular plas- plasmids, already more than 40 years ago (Ericson mids (Littlejohn et al.
    [Show full text]
  • Subject: Manufacturing of Synthetic Organic Chemicals (API's: 400Kg
    Subject: Manufacturing of Synthetic Organic Chemicals (API’s: 400Kg/day + R&D: 33.3Kg/day) at Plot No. 4, Industrial Park, Attivaram Village, Ozili Mandal, SPSR Nellore District, Andhra Pradesh by M/s. Balaji Chirex Pvt. Ltd., - reg. Project proposal: M/s. Balaji Chirex Pvt. Ltd., proposed to establish a Synthetic Organic Chemical Manufacturing Unit at Plot No. 4, Industrial Park, Attivaram Village, Ozili Mandal, SPSR Nellore District, Andhra Pradesh. The company acquired 4.515 acres of land for the proposed plant and allocated 1.49 acres of the area for green belt. The site is surrounded by internal IDA road in north direction, Shimoga Life Sciences Pvt. Ltd., in east direction and open plots in south and west directions. The nearest human settlement from the site is Attivaram village located at distance of 1.1 km from the site. Mamidi Kalva is at a distance of 4.28 km in southwest direction, flowing from northeast to southwest. Attivaram RF at a distance of 0.5 Km in east, Jayampu RF at a distance of 7 Km in northwest, Permidi RF at a distance of 5 Km in southwest and Sangavaram RF at a distance of 4.5 Km in southwest directions respectively. There are no national parks or sanctuaries within 10 km radius of the site. Total capital cost of the project is Rs. 5 Crores. Manufacturing capacity is presented as follows; Manufacturing Capacity S.No Name of the Product Capacity Kg/Month Kg/Day 1 Alfuzosin 50 1.7 2 Allantion 200 6.7 3 Aripiprazole 100 3.3 4 Calcium Ascorbate 500 16.7 5 Calcium Aspartate 1000 33.3 6 Calcium Citrate Malate 2000
    [Show full text]
  • ANNEX VI List of Preservatives Allowed for Use in Cosmetic Products
    ANNEX VI List of preservatives allowed for use in cosmetic products ANNEX VI LIST OF PRESERVATIVES WHICH COSMETIC PRODUCTS MAY CONTAIN Preamble 1. Preservatives are substances which may be added to cosmetic products for the primary purpose of inhibiting the development of micro-organisms in such products. 2. The substances marked with the symbol (+) may also be added to cosmetic products in concentration other than those laid down in this ANNEX for other purposes apparent from the presentation of the products, e.g. as deodorants in soaps or as anti-dandruff agents in shampoos. 3. Other substances used in the formulation of cosmetic products may also have anti-microbial properties and thus help in the preservation of the products, as, for instance, many essential oils and some alcohols. These substances are not included in the ANNEX. 4. For the purposes of this list - “Salts” is taken to mean: salts of the cations sodium, potassium, calcium, magnesium, ammonium, and ethanolamines; salts of the anions chloride, bromide, sulphate, acetate. - “Esters” is taken to mean: esters of methyl, ethyl, propyl, isopropyl, butyl, isobutyl, phenyl. 5. All finished products containing formaldehyde or substances in this ANNEX and which release formaldehyde must be labelled with the warning “contains formaldehyde” where the concentration of formaldehyde in the finished product exceeds 0.05%. Revised as per August 2015 ASEAN Cosmetic Documents 1 Annex VI – Part 1 – List of preservatives allowed for use in cosmetic products ANNEX VI – PART 1 LIST OF PRESERVATIVES ALLOWED Reference Substance Maximum authorized Limitations and Conditions of use and Number concentration requirements warnings which must be printed on the label a b c d e 1 Benzoic acid (CAS No.
    [Show full text]
  • Oral Magnesium Gly Magnesium Glycerophosphate Ceroph
    pat hways Preventing recurrent hypomagnesaemia: oral magnesium glycerophosphate Evidence summary Published: 29 January 2013 nice.org.uk/guidance/esuom4 Key points from the evidence The content of this evidence summary was up-to-date in January 2013. See summaries of product characteristics (SPCs), British national formulary (BNF) or the MHRA or NICE websites for up-to-date information. Magnesium glycerophosphate is a magnesium salt that is available as a tablet, capsule, liquid solution or liquid suspension for oral use. The British national formulary (BNF) states that oral magnesium glycerophosphate is a suitable preparation to prevent recurrence of symptomatic hypomagnesaemia in people who have already been treated for this condition. This evidence summary looks at the use of oral magnesium glycerophosphate in patients who have previously been treated with an intravenous infusion of magnesium. Oral magnesium glycerophosphate does not have UK marketing authorisation for this or any other indication, and therefore it is an unlicensed medicine in the UK. No published clinical trials comparing the efficacy of oral magnesium glycerophosphate with placebo or any form of active treatment for preventing recurrent hypomagnesaemia after treatment with intravenous magnesium were identified. The only videncee found was from 3 case reports describing the use of oral magnesium glycerophosphate for preventing recurrent hypomagnesaemia in adults after intravenous treatment. © NICE 2018. All rights reserved. Subject to Notice of rights (https://www.nice.org.uk/terms-and- Page 1 of conditions#notice-of-rights). 17 Preventing recurrent hypomagnesaemia: oral magnesium glycerophosphate (ESUOM4) Two of the 3 case reports concerned patients who had short bowel syndrome due to surgical resection.
    [Show full text]
  • In Vitro Efficacy of Bacterial Cellulose Dressings Chemisorbed with Antiseptics Against Biofilm Formed by Pathogens Isolated from Chronic Wounds
    Supplementary Materials In Vitro Efficacy of Bacterial Cellulose Dressings Chemisorbed with Antiseptics Against Biofilm Formed by Pathogens Isolated from Chronic Wounds Karolina Dydak 1, Adam Junka 1,*, Agata Dydak 2, Malwina Brożyna 1, Justyna Paleczny 1, Karol Fijalkowski 3, Grzegorz Kubielas 4, Olga Aniołek 5 and Marzenna Bartoszewicz 1 1 Department of Pharmaceutical Microbiology and Parasitology, Medical University of Wroclaw, 50-556 Wroclaw, Poland; [email protected] (K.D.); [email protected] (M.B.); [email protected] (J.P.); [email protected] (M.B.) 2 Faculty of Biological Sciences, University of Wroclaw, 51-148 Wroclaw, Poland; [email protected] 3 Department of Microbiology and Biotechnology, Faculty of Biotechnology and Animal Husbandry, West Pomeranian University of Technology, Szczecin, Piastow 45, 70-311 Szczecin, Poland; [email protected] 4 Faculty of Health Sciences, Wroclaw Medical University, 50-996 Wroclaw, Poland; [email protected] 5 Faculty of Medicine, Lazarski University, 02-662 Warsaw, Poland; [email protected] * Correspondence: [email protected]; Tel.: +48-889229341 Citation: Dydak, K.; Junka, A.; Dydak, A.; Brożyna, M.; Paleczny, J.; Abstract: Local administration of antiseptics is required to prevent and fight against biofilm-based Fijalkowski, K.; Kubielas, G.; infections of chronic wounds. One of the methods used for delivering antiseptics to infected wounds Aniołek, O.; Bartoszewicz, M. In is the application
    [Show full text]
  • Marketing Research on Dietary Supplements for Periodontitis in Patient Diabetes
    Original Study MARKETING RESEARCH ON DIETARY SUPPLEMENTS FOR PERIODONTITIS IN PATIENT DIABETES Galyna Biloklytska, Svitlana Viala, Alina Koval* National Medical Academy of Postgraduate Education named after P. L. Shupyk, Kyiv, Ukraine. ABSTRACT The vast majority of periodontal diseases are inflammatory and can develop under the influence of both local causes and the combined action of common (endogenous) and local factors against the background of changes in the reactivity of the body. In the pathogenesis of the development of periodontal diseases in patients with diabetes, the main role is given to angiopathies. Since periodontitis is characterized by various vascular disorders, which are largely similar to diabetic angiopathy, it is not easy to prove the presence of the latter with periodontitis. So some authors argue this, while, others deny it. The starting point of diabetic microangiopathies is a violation of carbohydrate metabolism, as well as a violation of glycosamine metabolism, which determines the functional and structural integrity of the vascular basement membrane. Key words: producing countries, periodontitis, diabetes mellitus, dietary supplements, medicines, dentistry. Introduction the treatment and prevention of such pathology, as periodontitis in patients with diabetes. Nowadays, the problem of treatment and rehabilitation of patients with periodontitis is quite actual, as there is an The search for modern drugs and perspective combinations increase in morbidity among people of working age, of microelements for treatment, both internally and locally, increasing demands on appearance as a factor that plays an using applications on periodontal tissues in patients with important role in professional and personal success in various types of diabetes, involves marketing analysis of society.
    [Show full text]